Skip to main content

Advertisement

Table 5 The relationship between clinic-pathological characteristics and cancer specific survival in patients with primary operable invasive ductal breast cancer

From: Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer

All patients (n = 360) Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age (≤50/ >50 years) 0.97(0.64-1.45) 0.861   
Size (≤20/ 21-50/ >50 mm) 2.16(1.52-3.05) <0.001 1.58(1.09-2.29) 0.014
Grade (I / II / III) 1.84(1.31-2.57) <0.001 1.43(1.00-2.05) 0.049
Involved lymph node (-ve/+ve) 2.83(1.87-4.28) <0.001 1.82(1.17-2.83) 0.008
ER (no/yes) 0.59(0.39-0.89) 0.012   0.571
PR (no/yes) 0.72(0.48-1.09) 0.128   
HER2 status (no/yes) 1.34(0.84-2.14) 0.216   
Endocrine therapy (no/yes) 0.48(0.26-0.88) 0.018   0.114
Chemotherapy (no/yes) 1.56(1.05-2.33) 0.029   0.611
LBVIH&E (absent/present) 2.39(1.61-3.54) <0.001   0.196
LVID2–40 (absent/present) 3.31(2.19-4.97) <0.001 1.69(1.08-2.67) 0.023
BVIFVIII (absent/present) 5.12(3.38-7.78) <0.001 3.35(2.21-5.63) <0.001
Node-negative patients (n = 212)     
age (≤50/ >50 years) 0.69(0.36-1.36) 0.290   
Size (≤20/ 21-50/ >50 mm) 2.33(2.32-3.31) 0.007 1.93(1.04-3.59) 0.038
Grade (I / II / III) 1.64(1.64-2.74) 0.061   0.184
ER (no/yes) 0.75(0.38-1.45) 0.388   
PR (no/yes) 0.91(0.47-1.78) 0.780   
HER2 status (no/yes) 2.11(1.03-4.31) 0.040   0.368
Endocrine therapy (no/yes) 0.91(0.41-2.02) 0.822   
Chemotherapy (no/yes) 0.83(0.39-1.72) 0.612   
LBVIH&E (absent/present) 2.43(1.21-4.89) 0.010   0.649
LVID2–40 (absent/present) 3.24(1.67-6.29) 0.001 2.29(1.15-4.58) 0.004
BVIFVIII (absent/present) 6.03(2.87-13.77) <0.001 4.43(2.07-9.51) 0.001
Triple-negative patients (n = 120)     
age (<50/ >50 years) 1.09(0.57-2.01) 0.784   
Size (≤20/ 21-50/ >50 mm) 3.43(2.01-5.85) <0.001 2.94(1.65-5.24) <0.001
Grade (I / II / III) 0.79(0.39-1.58) 0.503   
Involved lymph node (-ve/+ve) 4.08(2.01-8.27) <0.001 2.36(1.11-5.03) 0.026
Endocrine therapy (no/yes) 0.89(0.27-2.89) 0.842   
Chemotherapy (no/yes) 0.93(0.48-1.78) 0.824   
LBVIH&E (absent/present) 2.31(1.21-4.42) 0.011   0.294
LVID2–40 (absent/present) 3.57(1.82-7.04) <0.001 2.61(1.36-5.04) 0.014
BVIFVIII (absent/present) 4.68(3.09-10.31) <0.001 3.63(1.38-6.56) 0.001